LitAlert ~~ GeneLit.com

    • A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
    • Gao B, Voskoboynik M, Cooper A, Wilkinson K, Hoon S, Hsieh CY, Cai S, Tian YE, Bao J, Ma N, Wang C, Zhang M, Li B, Guo M, Zhou R, Wang X, Xu C, de Souza P.
    • Cancer. 2023 Jan 31. doi: 10.1002/cncr.34662. Epub ahead of print.

    Related:

    •• Identifier: NCT03507543: The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Response to Ovarian Stimulation for Urgent Fertility Preservation before Gonadotoxic Treatment in BRCA-Pathogenic-Variant-Positive Breast Cancer Patients.
    • El Moujahed L, Philis R, Grynberg M, Laot L, Mur P, Amsellem N, Mayeur A, Benoit A, Rakrouki S, Sifer C, Peigné M, Sonigo C.
    • Cancers (Basel). 2023 Jan 31;15(3):895. doi: 10.3390/cancers15030895.

    • Germline Testing in Prostate Cancer: Implementation and Disparities of Care.
    • Brown LC, Armstrong AJ.
    • JCO Oncol Pract. 2023 Jan 31:OP2200804. doi: 10.1200/OP.22.00804. Epub ahead of print.

    • Dr. King on Delays in Access to Germline Testing in Pancreatic Cancer.
    • King D.
    • OncLive. OncLive TV. 2023 Jan 31.

    • Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study.
    • Tavano F, Gioffreda D, Fontana A, Palmieri O, Gentile A, Latiano T, Latiano A, Latiano TP, Scaramuzzi M, Maiello E, Bazzocchi F, Perri F.
    • Mol Med. 2023 Jan 30;29(1):14. doi: 10.1186/s10020-023-00600-1.

    • Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
    • Penson RT, Ambrosio AJ, Whalen CA, Krasner CN, Konstantinopoulos PA, Bradley C, Matulonis UA, Birrer MJ.
    • Oncologist. 2023 Jan 30:oyac275. doi: 10.1093/oncolo/oyac275. Epub ahead of print.

    Related:

    •• Identifier: NCT01033123: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    •• Identifier: NCT01033292: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Variations in Practice and Geographic Disparities Between Dedicated Multidisciplinary Clinics for BRCA1/BRCA2 Mutation Carriers in Israel.
    • Hermann N, Mor P, Kaidar-Person O, Bernstein-Molho R, Brodsky M, Madorsky Feldman D, Flugelman AA, Aboody Nevo H, Meshoulam Avital D, Sklair-Levy M, Friedman E, Allweis TM.
    • Isr Med Assoc J. 2023 Jan;25(1):18-22.